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CocoaAccumulating data suggest that diets rich in ﬂavanols and procyanidins are beneﬁcial for human health. In
this context, there has been a great interest in elucidating the systemic levels and metabolic proﬁles at
which these compounds occur in humans. Although recent progress has been made, there still exist consid-
erable differences and various disagreements with regard to the mammalian metabolites of these com-
pounds, which in turn are largely a consequence of the lack of availability of authentic standards that
would allow for the directed development and validation of expedient analytical methodologies. In this
study, we developed a method for the analysis of structurally related ﬂavanol metabolites using a wide
range of authentic standards. Applying this method in the context of a human dietary intervention study
using comprehensively characterized and standardized ﬂavanol- and procyanidin-containing cocoa, we
were able to identify the structurally related (−)-epicatechin metabolites (SREM) postprandially extant in
the systemic circulation of humans. Our results demonstrate that (−)-epicatechin-3′-β-D-glucuronide,
(−)-epicatechin-3′-sulfate, and a 3′-O-methyl-(−)-epicatechin-5/7-sulfate are the predominant SREM in
humans and further conﬁrm the relevance of the stereochemical conﬁguration in the context of ﬂavanol me-
tabolism. In addition, we also identiﬁed plausible causes for the previously reported discrepancies regarding
ﬂavanol metabolism, consisting, to a signiﬁcant extent, of interlaboratory differences in sample preparation
(enzymatic treatment and sample conditioning for HPLC analysis) and detection systems. Thus, these ﬁnd-
ings may also aid in the establishment of consensus on this topic.
© 2011 Elsevier Inc.Open access under CC BY-NC-ND license.Flavanols and their oligomeric derivatives, the procyanidins, belong
to a subclass of ﬂavonoids widely present in the human diet, particular-
ly in food and beverages such as tea, wine, cocoa, apple, plums, pome-
granates, and berries [1–3]. Accumulating data from medical
anthropological [4], epidemiological [5–7], and dietary intervention
studies [8–15] support the notion that the consumption of a diet rich
in ﬂavanols and procyanidins decreases the incidence of morbidity
and mortality from cardiovascular diseases. This concept has been fur-
ther substantiated by recent studies demonstrating that the presence
of individual ﬂavanols, such as (−)-epicatechin, in food can, at least in
part, be causally linked to the beneﬁcial vascular effects observed after
consumption of ﬂavanol- and procyanidin-containing foods [16–18].
In this context, there is an increasing interest in elucidating the mecha-
nisms by which the consumption of these compounds, in particularextraction; UVD, ultraviolet
D, electrochemical detection;
uronidase; SREM, structurally
i).
-NC-ND license.(−)-epicatechin,mediates the observed effects [19]. However, ingested
(−)-epicatechin is metabolized into a wide range of metabolites, in-
cluding structurally related (−)-epicatechin metabolites (SREM)1,
which maintain an intact ﬂavanol ring, and ring-ﬁssion metabolites,
originating from (−)-epicatechin breakdown by gut microbiome.
Therefore, it is essential to elucidate the speciﬁc chemical structures
and levels of (−)-epicatechin metabolites that are systemically present
in humans, as these metabolic derivatives may represent the molecules
actually eliciting the effects observed after (−)-epicatechin consump-
tion [17,18]. In this context, and considering that the vascular effects ob-
served after (−)-epicatechin intake are temporally and quantitatively
correlated with SREM in circulation [17,18], establishing the chemical
structure of this particular group of metabolites is critical.
There are several studies that have reported on the absorption and
metabolism of (−)-epicatechin in humans and other mammalian
species [17,20–24]. Thus far, it has been clearly established that
ingested (−)-epicatechin is extensively metabolized into SREM by
O-methylation, O-sulfonation, O-glucuronidation, and combinations
thereof [25–28]. Consequently, the potential postprandial proﬁle of
SREM is of considerable broadness with regard to the properties of
its individual constituents in terms of chemical structure, molecular
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protein-binding capacity, and others. Thus, it may not be surprising
that there exist discrepancies in the literature with regard to the pre-
cise structure and abundance of the main SREM systemically present
in humans [17,21,23]. Although several factors can be postulated to
contribute to these discrepancies (e.g., food matrix effects on absorp-
tion, intake amount-dependent differences, interindividual varia-
tions), at this point in time, a signiﬁcant part of the causes
underlying this issue may essentially lie in methodological differ-
ences, such as sample preparation and chromatographic analyses.
Current sample preparation and conditioning methods vary greatly
across studies [24,25,29–33], as do the chromatography and detection
systems [23,33,34]. Consequently, when considering the broadness of
the potential SREM spectrum, the wide-ranging interlaboratory dif-
ferences in sample preparation and analytical methods may represent
a key contributing factor in the substantial differences with regard to
the reported levels and relative abundance of particular metabolites.
This argument is further supported by considering that none of the
currently published methods of either sample preparation or chroma-
tography was validated against an array of authentic standards that
reﬂects the postprandial SREM spectrum in terms of its broad range
of physicochemical properties. Consequently, the numerical values
for systemic levels of SREM that are currently reported in the litera-
ture carry a signiﬁcant burden of uncertainty. On the surface this
issue may seem of a somewhat specialized technical nature, but on
the contrary, the correct identiﬁcation of (−)-epicatechin metabo-
lites and their consistent and accurate measurement across investiga-
tor groups is essential not only for characterizing and elucidating the
potential metabolites driving (−)-epicatechin-mediated bioactivities
in humans, but also for meaningfully assessing dietary intake, investi-
gating cause–effect relationships with regard to potential health ben-
eﬁts, and thus ultimately translating our collective knowledge into
recommendations for primary and secondary prevention, dietary
guidelines, and public health.
In this study, using a wide range of de novo chemically synthe-
sized authentic (−)-epicatechin metabolite standards, we developed
a method to assess the postprandial proﬁle of SREM extant in the
systemic circulation of humans. This methodology was subsequently
applied in the context of a controlled dietary intervention study in
healthy male adult volunteers. The results obtained were evaluated
and are discussed in the context of previous data.
Materials and methods
Materials
Authentic, chemically de novo synthesized (−)-epicatechin metabolite
standards, including 3′-O-methyl-(−)-epicatechin, 4′-O-methyl-
(−)-epicatechin, and the ammonium salts of (−)-epicatechin-4′­sulfate,
(−)-epicatechin-3′­sulfate, (−)-epicatechin-5­sulfate, (−)-epicatechin-
7­sulfate, (−)-epicatechin-7-β-D-glucuronide, (−)-epicatechin-3′-
β-D-glucuronide, 3′­O­methyl-(−)-epicatechin-7-β-D-glucuronide,
4′­O­methyl-(−)-epicatechin-5-β-D-glucuronide, 4′­O­methyl-(−)-
epicatechin-7-β-D-glucuronide, 4′­O­methyl-(−)-epicatechin-3′-β-D-
glucuronide, and 3′-O-ethyl-(−)-epicatechin (recovery standard) were
provided by Mars, Inc. (Hackestown, NJ, USA). (−)-Epicatechin and
sulfatase and β­glucuronidase enzymes were purchased from Sigma
(Saint Louis, MO, USA). Water, N,N-dimethyl formamide, methanol,
and acetonitrile HPLC grade were purchased from Fisher (Pittsburgh,
PA, USA).
Sample preparation for the identiﬁcation and quantiﬁcation of individual
(−)-epicatechin metabolites in human plasma
The sample preparation method was adapted from Unno et al. [32]
and further developed. One milliliter of plasma was spiked with 50 μlof a solution containing 10 μM 3′­O­ethyl-(−)­epicatechin (recovery
standard) and diluted with 2 ml of 3.4% (w/v) phosphoric acid. There-
after, samples were loaded onto solid-phase extraction (SPE) car-
tridges (Oasis HLB 60 mg, 3 cc) previously conditioned with 1 ml of
N,N-dimethyl formamide (DMF):methanol (7:3) and 0.5% (v/v) acetic
acid in water. The washing steps consisted of 3 ml of 0.5% (v/v) acetic
acid in water, 1 ml of water:methanol:acetic acid (80:20:0.5), and
1 ml of 0.5% (v/v) acetic acid in acetonitrile. For elution, cartridges
were dried and eluted with the addition of 1 ml of DMF:methanol
(7:3) twice. The eluate was collected in tubes containing 200 μl of
0.5% (v/v) acetic acid in methanol. The total volume was reduced to
approximately 50 μl using a Speedvac concentrator (Thermo Electron
Corp., SPD131DDA-115) at 2–3 mm Hg pressure and refrigerated
vapor trap (Thermo Electron Corp., RVT4101-115) working at
−100 °C. Samples were then mixed with a solution containing 75
pmol of catechol and 300 pmol of resorcinol (internal standards)
and analyzed by HPLC within 24 h.
To determine the extraction efﬁciency (i.e., recovery) of (−)-
epicatechin metabolites, plasma samples were spiked with increasing
concentrations of the (−)-epicatechin metabolites to generate ﬁnal
concentrations ranging from 10 to 1000 nM. These samples were ana-
lyzed applying the method described above. For comparison purposes,
plasma samples spiked with select (−)-epicatechin metabolites were
analyzed using a different sample conditioning method, which was
based on protein precipitation with methanol as described elsewhere
[35].
Sample preparation for the quantiﬁcation of (−)-epicatechin metabolites
in human plasma using differential hydrolysis
To assess the presence of those (−)-epicatechin metabolites for
which we do not have standards and to further compare the results
obtained using the direct quantiﬁcation of individual metabolites,
we quantiﬁed (−)-epicatechin metabolites in plasma using differen-
tial hydrolysis. This method is based on the treatment of plasma sam-
ples with arylsulfatase (aSL) and β-glucuronidase (βGL), enzymes
that speciﬁcally hydrolyze (−)-epicatechin sulfates and glucuronides,
respectively, giving rise to (−)-epicatechin, 3′-O-methyl-(−)-epica-
techin, and 4′-O-methyl-(−)-epicatechin that are later quantiﬁed in
the samples. Using this approach it is possible to identify the follow-
ing groups of (−)-epicatechin metabolites: (−)-epicatechin glucuro-
nides, 3′-O-methyl-(−)-epicatechin glucuronides, 4′-O-methyl-(−)-
epicatechin glucuronides, (−)-epicatechin sulfates, 3′-O-methyl-
(−)-epicatechin sulfates, and 4′-O-methyl-(−)-epicatechin sulfates.
To select suitable aSL and βGL enzymes to be used in this study, we
compared the extent of hydrolysis of surrogate O-glucuronidated
and O-sulfonated metabolites (4-nitrophenyl-β-D-glucuronide and
nitrocatechol sulfate, respectively) in plasma using aSL and βGL from:
(i) Helix pomatia (13.1 kIU/ml of βGL and 0.32 kIU/ml of aSL),
(ii) agglutinin-free H. pomatia (9.0 kIU/ml of βGL and 0.04 kIU/ml of
aSL), (iii) Escherichia coli (9.8 kIU/ml of βGL) and abalone entrails
(0.14 kIU/ml of aSL), and (iv) Patella vulgata (22.1 kIU/ml of βGL and
0.39 kIU/ml of aSL) (Fig. 1). The results obtained demonstrated that
aSL and βGL from H. pomatia exerted a complete hydrolysis of the sur-
rogate metabolites. In addition, these enzymes were capable of hy-
drolyzing a series of authentic (−)-epicatechin metabolite standards,
including (−)-epicatechin-4′­sulfate, (−)-epicatechin-7-β-D-glucuro-
nide, 3′­O­methyl-(−)-epicatechin-7-β-D-glucuronide, 4′­O­methyl-
(−)-epicatechin-5-β-D-glucuronide, 4′­O­methyl-(−)-epicatechin-7-
β-D-glucuronide, and 4′­O­methyl-(−)-epicatechin-3′-β-D-glucuronide
(data not shown). Importantly, although β­glucuronidase from
bovine liver was effective at catalyzing the complete hydrolysis
of O-glucuronidated metabolites, O-sulfates remained unaffected
by these enzymes.
The quantiﬁcation of (−)-epicatechin, 3′-O-methyl-(−)-epicatechin,
and 4′-O-methyl-(−)-epicatechin in plasma was determined in 0.5 ml
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Fig. 1. Extent of hydrolysis of O-glucuronidated and O-sulfonated metabolites in plasma.
Hydrolysis catalyzed by β-glucuronidase (βGL) and arylsulfatase (aSL) enzymes from
(i) H. pomatia, (ii) agglutinin-free H. pomatia, (iii) E. coli and abalone entrails, and
(iv) P. vulgata. Data are expressed as means±SEM of the percentage of the metabolites
hydrolyzed. *pb0.01, signiﬁcantly different from the control (100% hydrolysis).
Table 1
Composition of the test drink used in Study I.
Nutritional details Amount received
Calories (kcal) 224
Total fat (g) 19
Saturated fat (g) 3
Cholesterol (mg) 19
Total carbohydrates (g) 29
Dietary ﬁber (g) 3
Sugars (g) 24
Caffeine (mg) 35
Theobromine (mg) 297
Total ﬂavanols and procyanidins (mg) 1100
(−)-Epicatechin (mg) 138
(±)-Catechin (mg) 19
Procyanidins (dimers to decamers) (mg) 944
Values represent the amounts that would have been consumed by a 75-kg subject.
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3′­O­ethyl-(−)­epicatechin (recovery standard) acidiﬁed with 50 μl of
1.2 M acetic acid and incubated for 40 min at 37 °C in the presence of
5000 IU of β­glucuronidase and at least 150 IU of aSL from H. pomatia
or 5000 IU of βGL from bovine liver. Thereafter, samples were put on
ice, dilutedwith 1.3 ml of 0.5% (v/v) acetic acid inwater, and centrifuged
for 15 min at 16,500 g at 4 °C. Finally, samples were loaded onto SPE car-
tridges following the same protocol as for the determination of individu-
al metabolites, with the exception of the second washing step that was
done using 1 ml of water:methanol:acetic acid (70:30:0.5).
To determine the extraction efﬁciency (i.e., recovery) of (−)-
epicatechin, 3′-O-methyl-(−)-epicatechin, and 4′-O-methyl-(−)-
epicatechin, plasma samples containing aSL and βGL from H. pomatia
were spiked with increasing concentrations of the above metabolites
to generate ﬁnal concentrations ranging from 10 to 1000 nM. These
samples were incubated for 40 min at 37 °C and analyzed using the
method described above. For comparison purposes, plasma samples
spiked with the same compounds were analyzed using a different sam-
ple conditioning method, which was based on protein precipitation
with methanol as described elsewhere [35].
Chromatographic conditions for the quantiﬁcation of (−)-epicatechin
metabolites
(−)-Epicatechin and its related metabolites were resolved and
quantiﬁed using an Agilent HPLC 1100 series equippedwith a quaterna-
ry pump, autosampler, column and sample thermostat, UV/Vis (UVD)
and ﬂuorescence detectors (FLD), and an ESA Coulochem array detector
(ECD), Model 5600A, equipped with a Cell Model 6210 with an array of
four electrodes. Chromatography was based on a Phenomenex Luna
C18(2) column (150×4.6 mm, 3-μm particle size) with guard column.
The separation and resolution of compounds was achieved using the
elution program as described by Ottaviani et al. [35]. The detection of
(−)-epicatechin and its related metabolites was done following the
traces ofﬂuorescence at 276 nmexcitation and 316 nmemission, UV ab-
sorption at 280 nm, and oxidation at 225, 350, 425, and 550 mV.
Identiﬁcation of individual metabolites using HPLC–MS/MS and enzymatic
hydrolysis
Peaks designated as potential SREM were initially identiﬁed based
on a retention time comparison with authentic (−)-epicatechinmetabolite standards, ﬂuorescence emission spectra (from 301 to
400 nm), UV-absorbance spectra (from 200 to 400 nm), the ratio of
ﬂuorescence vs UV intensity, and electrochemical detection (at 225,
350, 425, and 550 mV). To further substantiate the identity of the
metabolites detected, samples from different subjects were analyzed
using the chromatographic conditions described above, and the putative
SREM peaks were collected. An aliquot of the collected fractions was
incubated in the presence of aSL or βGL enzyme, and the products of
hydrolysis were analyzed by HPLC as described above. Other aliquots
of collected fractions were analyzed by HPLC–MS/MS, using an Agilent
HPLC 1100 Series LC equipped with a Metachem Polaris C18-A column
(4.6×250 mm, 3 μm particle size) coupled to an AB Sciex API 4000
QTrap mass spectrometer with a turbo ion spray source in negative-ion
mode. AB Sciex Analyst version 1.5 software was used for data analyses.
The chromatographic conditions consisted of a linear gradient from A to
B at constant ﬂow rate of 0.5 ml/min starting with 100% A for 1 min, con-
tinuing with a linear increase of B up to 100% in 25 min, and maintaining
100% B for 1 min more; solution A was 10mM ammonium acetate in
water:acetonitrile (95:5) and B was 10 mM ammonium acetate in
water:acetonitrile (5:95). The identiﬁcation of (−)-epicatechin metabo-
lites was conductedwith the followingm/z transition: 369→ 289 (epica-
techin sulfates), 465→ 289 (epicatechin glucuronides), 383→ 289 and
383→ 303 (O-methylepicatechin sulfates), 479→ 113 (O-methylepica-
techin glucuronides), 305 → 109 (O-methylepicatechin), and 289 →
109 (epicatechin). The ion spray and oriﬁce voltages, temperature, and
collision energywere set at−4200 V,−65 V, 500 °C, and−36 V, respec-
tively. The collision gas (nitrogen)wasmaintained at themedium setting.
Data acquisition was conducted using multiple-reaction monitoring
with a 75-ms dwell time per transition.Human Study I: identiﬁcation and quantiﬁcation of (−)-epicatechin
metabolites in circulation
(−)-Epicatechin-containing test drink
The test drink consisted of a cocoa dairy-based drink containing
(−)-epicatechin in addition to other ﬂavanols and procyanidins. The
amount of the test compound consumed by each participant was
identical in terms of amount per kilogram of body weight (bw). The
test drink was prepared by mixing 0.5 g/kg bw low­ﬂavanol cocoa
powder, 5 g/kg bw milk (1% fat), and 22 mg/kg bw cocoa extract con-
taining 47.7% (w/w) ﬂavanols and procyanidins (as determined using
the method detailed in [36]). The resulting amount of (−)-epicate-
chin consumed with the drink was 1.8 mg of (−)-epicatechin/kg
bw. The content of macronutrients and caloric load, as well as the
amounts of theobromine, caffeine, and other ﬂavanols and procyani-
dins in the drink, are listed in Table 1. This drink was similar in com-
position to ﬂavanol-rich drinks that have been reported to induce an
acute vascular response in humans after consumption [10,13]. The
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ﬂavanol cocoa powder were supplied by Mars, Inc. (Hackettstown,
NJ, USA).
Participants
We screened healthy male volunteers between 18 and 35 years of
age. Main exclusion criteria were a body mass index higher than
30 kg/m2; a history of cardiovascular, renal, or liver disease, gastroin-
testinal disorders, or previous gastrointestinal surgery; smoking
within the 5 years before the initialization of the study; current con-
sumption of herbal, antioxidant, or vitamin supplements; and exist-
ing allergies to peanuts or milk. To reduce the contribution of
ﬂavanols from the diet, participants were asked to follow a low-
ﬂavanol diet on the day before and during the study days. All volun-
teers were instructed on how to follow a low-ﬂavanol diet, receiving
a list of suggested foods containing low or negligible amounts of ﬂa-
vanols. In addition, we provided the volunteers with ﬂavanol-free
foods for their supper on the day before the study day, as well as for
all the meals during the study day. Volunteers were asked to restrain
from consuming alcohol, coffee, or other caffeine-containing bever-
ages on the day before and during the study visits. Volunteers were
asked to fast for 12 h before each study day (water ad libitum).
Study design
Upon arrival, volunteers (n=10) received 4 g/kg bw drinking
water to control for the level of hydration. One hour later, volunteers
were given the test drink and were asked to consume it within 5 min.
Venous blood samples were taken using EDTA-containing Vacutai-
ners at 0 h (before intake) and 1, 2, and 4 h after drink ingestion. Plas-
ma was obtained by whole-blood centrifugation at 1800 g for 15 min
at 4 °C, separated into aliquots, and spiked with ascorbic acid (ﬁnal
concentration: 1 mg/ml). Plasma samples were stored at −80 °C
until analysis.
Volunteers participated in the study on different days, and the
study was completed in 4 weeks. This study protocol was approved
by the Institutional Review Board of the University of California at
Davis, and all subjects gave their written informed consent to
participate.
Human Study II: comparison of (+)- and (−)-epicatechin metabolites
in circulation
To compare the proﬁle of SREM after the consumption of (+)- and
(−)-epicatechin we reanalyzed samples that were originally generat-
ed from a study aimed at investigating the effects of ﬂavanol stereo-
chemistry on absorption and O-methylation [35]. Although that
investigation did not concern itself with assessing the O-sulfonated
and O-glucuronidated metabolites, a reprobing of the plasma samples
collected would provide valuable insights with regard to the
stereochemistry-speciﬁc aspects of ﬂavanol sulfonation and glucuro-
nidation. This reanalysis was limited to samples collected 2 h after
the consumption of 1.5 mg/kg bw (−)- and (+)-epicatechin in
healthy adult humans (n=7). For further details on the study design,
test drink, and study group, please refer to [35].
Statistical analysis
The primary test for an effect was a test of the interaction in a two-
way repeated-measures ANOVA (in which the factors were time and
the various metabolites). The ANOVA and Tukey p values as well as
the Pearson product motion correlation coefﬁcient (r) were comput-
ed with SigmaStat 3.5 (Systat Software, San Jose, CA, USA). p values of
0.05 or less were considered statistically signiﬁcant. To compare var-
iances of the recoveries obtained with SPE and protein precipitation,
we used the F test for equal variance. pb0.05 indicated that variances
of both groups were not equal.Results
Characterization of (−)-epicatechin metabolite standards, sample
preparation method, and the HPLC detection systems used
For this study we used a total of 12 authentic (−)-epicatechin me-
tabolite standards. The chemical identity of these standards is sup-
ported by an unambiguous de novo chemical synthesis and by 1H
NMR, 13 C NMR, and mass spectrometric analyses (Supplementary
Scheme I and Supplementary Figs. 1–3). Additionally, we present
HPLC chromatogram traces demonstrating the resolution and detec-
tion of all 12 (−)-epicatechin metabolite standards using UVD, FLD,
and ECD as described under Materials and methods (Fig. 2). Although
all of the metabolite standards can be detected after UV absorbance at
280 nm, the detectability of these compounds based on FLD and ECD
methods varied signiﬁcantly. For instance, metabolites bearing a free
catechol group were detected with high sensitivity and selectivity
using ECD at an electrochemical potential of 225 mV (Fig. 2). Con-
versely, metabolites with a conjugated catechol group were detected
only at higher potentials (550 mV). Whereas most metabolite stan-
dards were detected using FLD, (−)-epicatechin sulfates exhibited a
very low ﬂuorescence signal and therefore were unquantiﬁable by
this detection method. The optimal conditions identiﬁed for the
quantiﬁcation of each of (−)-epicatechin metabolite standards inves-
tigated in this study are listed in Table 2.
Additionally, this series of (−)-epicatechin metabolite standards
was used to determine the extraction efﬁciency (i.e., recovery) of
these compounds from plasma using a solid-phase extraction meth-
od, as described under Materials and methods. The recoveries
obtained for this series of (−)-epicatechin metabolite standards ran-
ged from 74 to 100% (Table 2). Importantly, these recoveries were
higher (paired t test; pb0.001) and less variable (F test; pb0.05)
than the recoveries obtained by employing a more commonly used
sample conditioning method based on a plasma protein precipitation
approach with methanol (Table 2).
Study population
Basic biometric characteristics of the study group participating in
Study I are presented in Table 3. Baseline ﬂavanol concentrations in
plasma were below the limit of detection on each study day, indicat-
ing compliance with the low-ﬂavanol diet as detailed in the study
protocol. Volunteers reported no adverse events associated with
their participation in this study. For details on the study group partic-
ipating in Study II, please refer to Ref. [35].
Determination of the identity and concentration of individual
(−)-epicatechin metabolites in humans
Oral ingestion of the test drink resulted in the absorption of (−)-
epicatechin and the subsequent occurrence of various SREM in plasma
(Figs. 3 and 4). Despite the fact that (−)-epicatechin O-glucuronidation
could theoretically occur at ﬁve different sites on the (−)-epicatechin
molecule, one predominant (−)-epicatechin glucuronide was detected
in plasma. This metabolite corresponded to epicatechin-3′-β-D-glucuro-
nide (Fig. 3B). The identity of this metabolite was conﬁrmed by further
analysis of the collected peak by HPLC–MS/MS (peak detected at m/z
465→ 289) anddifferential enzymatic hydrolysis (βGL sensitive; product
of hydrolysis: (−)-epicatechin). The maximal plasma concentration of
epicatechin-3′-β-D-glucuronide (589±85 nM; pb0.05) was reached
within 2 h after the consumption of the test drink. Additionally, we also
detected the presence of signiﬁcantly smaller amounts of O-
methylated epicatechin glucuronides, particularly 4′-O-methyl-
(−)-epicatechin-7-β-D-glucuronide. This observation remained
qualitative, as the levels of this metabolite were below the limit
of quantiﬁcation (~20 nM for this compound).
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Fig. 2. Chromatogram traces of de novo synthesized authentic (−)-epicatechin metabolite standards. Detection with UV-absorbance (UVD), ﬂuorescence (FLD), and electrochemical
(ECD) detection at 225 and 550 mV, where peak A is (−)-epicatechin-7-β-D-glucuronide, B is 3′­O­methyl-(−)-epicatechin-7-β-D-glucuronide, C is (−)-epicatechin-3′-β-D-glucuronide,
D is 4′­O­methyl-(−)-epicatechin-5-β-D-glucuronide, E is (−)-epicatechin-5­sulfate, F is 4′­O­methyl-(−)-epicatechin-7-β-D-glucuronide, G is 4′­O­methyl-(−)-epicatechin-3′-β-D-glu-
curonide, H is (−)-epicatechin-7­sulfate, I is (−)-epicatechin, J is (−)-epicatechin-3′­sulfate, K is 3′-O-methyl-(−)-epicatechin, L is 4′-O-methyl-(−)-epicatechin, and RS is 3′-O-ethyl-
(−)-epicatechin. Inset: chemical structure of the authentic (−)-epicatechin metabolite standards used in this study that include metabolites derived from O-methylation (–CH3),
O-glucuronidation (–Gluc−), and O-sulfonation (–SO3−) in four different positions in the molecule, O4′ (R1), O3′ (R2), O5 (R3), and O7 (R4).
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of three distinct metabolites in plasma (Fig. 4B). The most abundant
compound of this series, (−)-epicatechin-3′-sulfate, reached a maxi-
mal plasma concentration of 331±26 nM at 2 h after consumption.
The other two sulfates corresponded to (−)-epicatechin-5-sulfate
and (−)-epicatechin-7-sulfate, both of which presented signiﬁcantly
lower plasma levels (37±3 and 12±1 nM, respectively) compared
to (−)-epicatechin-3′-sulfate. The identity of these (−)-epicatechin
derivatives was also veriﬁed via the collection of HPLC fractions and
further analysis by HPLC–MS/MS (peaks detected at m/z 369 →Table 2
Recovery of (−)-epicatechin metabolites from plasma samples using SPE (as described
under Materials and methods) and a protein precipitation method [35].
(−)-Epicatechin metabolite Recovery (%) Detection
system
Solid-phase
extraction
Protein
precipitation
Direct quantiﬁcation of individual metabolites
(−)-Epicatechin 93±1 76±1 ECD
(−)-Epicatechin-7-β-D-glucuronide 90±2 n.q. ECD/FLD
(−)-Epicatechin-3′-β-D-glucuronide 74±1 28±3 FLD
3′-O-Methyl-(−)-epicatechin-7-β-D-
glucuronide
86±4 60±1 FLD
4′-O-Methyl-(−)-epicatechin-5-β-D-
glucuronide
88±1 59±1 FLD
4′-O-Methyl-(−)-epicatechin-7-β-D-
glucuronide
101±1 62±1 FLD
4′-O-Methyl-(−)-epicatechin-3′-β-D-
glucuronide
72±2 49±1 FLD
(−)-Epicatechin-5-sulfate 85±1 n.q. ECD
(−)-Epicatechin-7-sulfate 84±1 n.q. ECD
(−)-Epicatechin-3′-sulfate 70±1 n.q. ECD
Differential hydrolysis
(−)-Epicatechin 82±1 78±1 FLD
3′-O-Methyl-(−)-epicatechin 73±1 109±3 FLD
4′-O-Methyl-(−)-epicatechin 78±1 103±2 FLD
Data are expressed as the average±SEM of the percentage recovered. Additionally, the
detection system used for quantiﬁcation for each metabolite is included. n.q., not
quantiﬁable (because of the presence of interfering peaks in the chromatogram
introduced via the protein precipitation method).289) and enzymatic hydrolysis (aSL sensitive; product of hydrolysis:
(−)-epicatechin). Furthermore, we also observed the presence of at
least four peaks that were collected by HPLC and analyzed by HPLC–
MS/MS (peaks detected at m/z 383→ 303) and enzymatic hydrolysis
(aSL sensitive; product of hydrolysis: 3′-O-methyl-(−)-epicatechin
(peaks i and ii) and 4′-O-methyl-(−)-epicatechin (peaks iii and iv)).
Therefore, the results obtained support the notion that these com-
pounds represent two individual 3′-O-methyl-(−)-epicatechin sul-
fates (peaks i and ii) and two distinct 4′-O-methyl-(−)-epicatechin
sulfates (peaks iii and iv) (Fig. 4B). Supporting this conclusion, further
analyses with authentic 3′-O-methyl-(−)-epicatechin sulfate stan-
dards demonstrated that sulfonation of the metabolites represented
by peaks i and ii occurred in positions O5 and O7, respectively.
Unmetabolized (−)-epicatechin was present in circulation at low
concentrations, reaching a maximum of 4±1 nM at 1 h after test
drink consumption. No free 3′/4′-O-methyl-(−)-epicatechin was
detected.Corresponding determination of plasma (−)-epicatechin metabolites
using differential hydrolysis
Corroborating the results detailed above, the analysis of plasma
samples using differential hydrolysis also identiﬁed (−)-epicatechin
glucuronides and (−)-epicatechin sulfates as major constituents of
the metabolome of (−)-epicatechin in humans (Fig. 5A). The levels
reached by (−)-epicatechin glucuronides were maximal 2 h after
consumption, presenting values of 573±77 nM (pb0.05). The con-
centration of (−)-epicatechin glucuronides as determined byTable 3
Study I participant characteristics.
Parameter (units) Value
Age (years) 32±1
Weight (kg) 75±8
BMI (kg/m2) 24±2
Systolic blood pressure (mm Hg) 123±9
Diastolic blood pressure (mm Hg) 74±8
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Fig. 3. Circulating (−)-epicatechin glucuronides. (A) Level of individual (−)-epicatechin glucuronides in plasma after the consumption of a test drink containing 1.8 mg/kg bw (−)-
epicatechin. Data are expressed as the average±SEM (n=10) in nM. (B) Chromatogram traces (FLD detection) of authentic (−)-epicatechin glucuronide standards and plasma
samples obtained before (0 h) and 2 h after consumption of the test drink, where peak A is (−)-epicatechin-7-β-D-glucuronide, B is 3′­O­methyl-(−)-epicatechin-7-β-D-glucuronide, C is
(−)-epicatechin-3′-β-D-glucuronide, D is 4′­O­methyl-(−)-epicatechin-5-β-D-glucuronide, F is 4′­O­methyl-(−)-epicatechin-7-β-D-glucuronide, and G is 4′­O­methyl-(−)-epicatechin-3′-
β-D-glucuronide.
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centration of (−)-epicatechin-3′-β-D-glucuronide as assessed using
authentic standards (r=0.995 and a slope of 1.03±0.02; pb0.001;
Fig. 5B). The group of (−)-epicatechin sulfates reached a maximal
plasma level of 301±30 nM at 2 h after consumption that was not
signiﬁcantly different from the sum of (−)-epicatechin-3′-sulfate,
(−)-epicatechin-5-sulfate, and (−)-epicatechin-7-sulfate as assessed
using authentic standards (r=0.952 and a slope of 1.12±0.03;
pb0.001; Fig. 5B). In addition, the use of differential hydrolysis per-
mitted the identiﬁcation and quantiﬁcation of two other groups of
(−)-epicatechin metabolites, namely the 3′- and 4′-O-methyl-(−)-
epicatechin sulfates. In this case, the maximal levels of 3′-O-methyl-
(−)-epicatechin sulfates were 214±26 nM at 2 h after consumption
(pb0.05), and the group of 4′-O-methyl-(−)-epicatechin sulfates
presented plasma levels of 51±8 nM (pb0.05).
Concurring with the ﬁndings using (−)-epicatechin metabolite
standards, the levels of 3′- and 4′-O-methylated (−)-epicatechin glu-
curonides represented a negligible fraction of the SREM in humans,
presenting values below 20 nM in plasma. No O-sulfonated or O-Time after consumption (h)
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5/7-sulfates.glucuronidated (−)-epicatechin metabolites were detected in the
samples.Relative abundance of (−)-epicatechin metabolites in humans
Combining the data that emanated from the use of differential hydro-
lysis with the data obtained using authentic standards, we are able to de-
tect and measure eight distinct postprandial metabolites of (−)-
epicatechin in human plasma. The identity of all eight metabolites was
further supported by HPLC–MS/MS. The most abundant (−)-epicatechin
metabolitewas (−)-epicatechin-3′-β-D-glucuronide,which accounted for
46±6% of all epicatechin metabolites detected in plasma at 2 h after
consumption (Fig. 6). The respective abundances of (−)-epicatechin-
3′-sulfate, (−)-epicatechin-5-sulfate, and (−)-epicatechin-7-sulfate
were 28±6, 3.1±0.8, and 1.1±0.3% of all epicatechin metabolites
identiﬁed (Fig. 6). The group of 3′- and 4′-O-methyl-(−)-epicatechin-
5/7-sulfates presented relative abundances of 17±2 and 4.3±0.7%,
respectively (Fig. 6).Elution time (min)
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metabolic fate in humans
We also investigated the inﬂuence of ﬂavanol stereochemistry on
the metabolic proﬁle of postprandial SREM after the ingestion by
humans of (−)-epicatechin and (+)-epicatechin. As depicted in
Fig. 7, the concentrations as well as relative abundances of individual
metabolites detected in plasma were highly dependent on the stereo-
chemical conﬁguration of the epicatechin ingested. Whereas
epicatechin-3′-β-D-glucuronide was the only O-glucuronidated me-
tabolite identiﬁed in plasma regardless of the epicatechin enantiomer
consumed, the maximal plasma concentration of this compound
reached 336±75 nM after (−)-epicatechin consumption, but only
13±7 nM after the ingestion of (+)-epicatechin (Fig. 7). Analogous-
ly, the concentration detected for epicatechin-3′-sulfate (377±49
nM) after (−)-epicatechin consumption was almost four times
higher than the concentration detected for the same metabolite
after (+)-epicatechin consumption (101±13 nM, pb0.05; Fig. 7).
In contrast, epicatechin-5-sulfate, which reached a level of 50±6Fig. 6. Relative amounts of individual (−)-epicatechin metabolites in plasma. Data
represent SREM proﬁle at 2 h after the consumption of a test drink containing
1.8 mg/kg bw (−)-epicatechin. *The abundance of these metabolites was calculated
according to the concentration determined by differential hydrolysis.nM after (−)-epicatechin intake, was extant at a concentration of
270±29 nM after (+)-epicatechin consumption (pb0.05; Fig. 7),
representing a ﬁvefold difference in favor of the (+) enantiomer.Discussion
In this study, we developed a method for the analysis of the post-
prandial proﬁle of SREM in human plasma samples. This method was
subsequently employed to assess (−)-epicatechin absorption and
metabolism after the consumption of a well-characterized and stan-
dardized ﬂavanol- and procyanidin-containing cocoa drink. Our
work resulted in the identiﬁcation of the chemical structures, plasma
concentrations, and relative abundances of the majority of SREM sys-
temically present in humans.
The development and testing of our method using a wide range of
de novo chemically synthesized (−)-epicatechin metabolite stan-
dards resulted not just in novel insights into ﬂavanol metabolism,
but also in the identiﬁcation of important limitations associated
with analytical methods in current use. For instance, the wideepicatechin-
5-sulfate
epicatechin-
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Fig. 7. Stereochemistry dependent epicatechin metabolism. Levels of individual
epicatechin metabolites in plasma after the consumption of a cocoa drink containing
1.5 mg/kg bw (−)-epicatechin or 1.5 mg/kg bw (+)-epicatechin. Data are expressed as
the average±SEM (n=7) in nM. *Signiﬁcantly different from the levels reached after
(−)-epicatechin consumption within the same metabolite, pb0.05.
1410 J.I. Ottaviani et al. / Free Radical Biology & Medicine 52 (2012) 1403–1412variation in sample conditioning/preparation methods, including
methods of plasma protein precipitation [35], is an important contrib-
uting factor to the widely varying yields in extraction efﬁciencies (re-
coveries) and therefore also to the differences in the reported relative
abundances of individual metabolites. For example, testing a range of
currently utilized sample preparation procedures, our data demon-
strated differences in the recovery of (−)-epicatechin-3′-β-D-glucu-
ronide that ranged from 28 to 74% (Table 2). In addition, the low
ﬂuorescence signal yielded by (−)-epicatechin sulfates, especially ev-
ident in the case of (−)-epicatechin-3′-sulfate, could explain why
previous investigations that exclusively relied on FLD detection sys-
tems were unable to detect and thus to recognize these metabolites
as a signiﬁcant part of the (−)-epicatechin metabolome in humans
[17,22]. Finally, it is also worth mentioning the considerable limita-
tions associated with the use of aSL and βGL to assess (−)-epicate-
chin levels and metabolism. In this context, we detected signiﬁcant
differences in the extent of hydrolysis of sulfates depending on the
origin of the enzymes utilized (Fig. 1). The limitations of using aSL
and βGL enzymes are also supported by previous reports suggesting
that 3′- and 4′-O-methyl-(−)-epicatechin sulfates are more resistant
to hydrolysis [37]. Consequently, these data indicate that the sole
dependency on enzymatic hydrolysis may lead to an underestimation
of the circulating levels of (−)-epicatechin metabolites, which should
be considered a limitation of data sets generated by using this method-
ological approach. Taken together, the results presented here clearly
demonstrate that the current ambiguity in the scientiﬁc literature
with regard to (−)-epicatechin levels and metabolism in mammals
can be attributed, at least in part, to the signiﬁcant differences in various
aspects of the analytical methods employed. In this context, we hope
that this study may contribute toward the building of a consensus
with regard to the analytical methodology used to assess the identity
and concentration of (−)-epicatechin metabolites in humans.
The application of our method in the context of a human dietary
intervention study resulted in the identiﬁcation, veriﬁcation, and
measurement of eight individual (−)-epicatechin metabolites, con-
sisting of (−)-epicatechin-3′-β-D-glucuronide, (−)-epicatechin-3′-
sulfate, (−)-epicatechin-5-sulfate, and (−)-epicatechin-7-sulfate.
Moreover, we described the presence of four distinct 3′- and 4′-O-
methyl-(−)-epicatechin sulfates, each of which is sulfonated in either
position O5 or position O7 of the epicatechin molecule.
Our ﬁndings demonstrate that (−)-epicatechin-3′-β-D-glucuronide
is the most predominant O-glucuronidated metabolic derivative
of (−)-epicatechin present in the human circulation. These results
are supported by previous quantitative or semiqualitative observa-
tions by Natsume et al., who originally described this metabolite inO
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Fig. 8. Schematic representation of the main circulating SREM based on assessments in h
UDP-glucuronosyltransferase; SULT, sulfotransferase; COMT, catechol O-methyltransferasehumans [21], and by more recent qualitative observations of a sin-
gle O-glucuronidated (−)-epicatechin metabolite present in plasma
after the consumption of various (−)-epicatechin-containing products
[23,24,38]. Unlike O-glucuronidation, (−)-epicatechin O-sulfonation
resulted in a more diverse group of metabolites in humans. Whereas
in the present study, a structural identiﬁcation of three distinct (−)-
epicatechin sulfates is provided for the ﬁrst time, Auger et al. previ-
ously reported on the presence of three O-sulfonated (−)-epicatechin
derivatives, the structures of which were not further elucidated [23].
Collectively, these ﬁndings substantiate the notion that O-sulfonation
is a key conjugating reaction in the metabolism of (−)-epicatechin in
humans, resulting in (−)-epicatechin-3′-sulfate as the most abundant
derivative of this series and one of the most abundant (−)-epicate-
chin metabolites in humans. Furthermore, we clearly demonstrated
that (−)-epicatechin O-methylation in humans occurs primarily in
the 3′ position of the (−)-epicatechin molecule, as is in accordance
with the catalytic properties of catechol O-methyltransferase [39].
Finally, we showed that (−)-epicatechin O-methylation ismainly extant
in combination with O-sulfonation, and not with O-glucuronidation,
as suggested in earlier investigations by our group and others
[17,21,22,31,40]. In this context, it is noteworthy that previous studies
describing the presence of O-methyl-(−)-epicatechin glucuronides
[21] administered (−)-epicatechin in amounts approximately 10 times
higher than consumed in the present study (ca. 20 mg/kg bw vs
1.8 mg/kg bw), suggesting the potential for (−)-epicatechin being sub-
jected to different metabolic pathways when consumed in quantities
that greatly exceed those relevant in a dietary context. Such a concept
would also be supported by previous ﬁndings on the metabolism of
monophenolic compounds in rats that also describe an amount-
dependent shift in O-sulfonation and O-glucuronidation [41,42]. In addi-
tion, other studies identifying the presence ofO-methyl-(−)-epicatechin
glucuronides in circulation were conducted in rats [31,40], also indicat-
ing the potential for species-dependent differences in the metabolism
of (−)-epicatechin. Taken together, it is tenable to conclude that in
humans, the consumption of diet-relevant amounts of (−)-epicatechin
leads to the presence in the systemic circulation of three predominant
and structurally related metabolites, including (−)-epicatechin-3′-β-
D-glucuronide, (−)-epicatechin-3′-sulfate, and a 3′-O-methyl-(−)-
epicatechin-5/7-sulfate (Fig. 8). Nonetheless, to establish the limits
of validity of these ﬁndings and to allow their population-based inter-
pretation, future investigations should address interindividual differ-
ences in (−)-epicatechin metabolism due to: (a) differences in
intake amount, food matrix, and consumption frequency; (b) varia-
tions in age, sex, race, and dietary and genetic background; and (c)
the inﬂuence of pathophysiological states and medications.H
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chemical conﬁguration as a determinant of ﬂavanol metabolism, our
results were somewhat unexpected. Although the intake of (+)-epi-
catechin resulted almost exclusively in the formation of O-sulfonated
derivatives, the main (−)-epicatechin metabolites included both O-
sulfonated and O-glucuronidated derivatives. Moreover, although
sulfonation of (+)-epicatechin took place at position O5, (−)-epica-
techin was predominantly sulfonated at the O3′ position. Thus,
these ﬁndings unequivocally demonstrate that the stereochemical
conﬁguration of ﬂavanols represents a major aspect determining the
resulting structure of ﬂavanol metabolites in humans. These ﬁndings
go beyond previous results reported by our group that demonstrated
stereoisomer-speciﬁc differences in the O-methylation of ﬂavanols in
humans [35]. In addition, our data demonstrate that the majority of
(−)-epicatechin metabolites identiﬁed in this study were those
with a conjugated catechol ring. As the catechol ring is often refer-
enced as a critical element in structure–activity relationships, espe-
cially with regard to the putative in vivo antioxidant properties of
ﬂavanols [43], the fact that this structure undergoes signiﬁcant meta-
bolic derivatization argues for a critical review of current assumptions
in this direction.
Overall, the results from this study provide a detailed description
of the systemic, postprandial proﬁle of SREM in humans, thus identi-
fying tenable candidate compounds that may represent the bioactive
principles in a causality chain linking the intake of ﬂavanol-
containing foods and the observed biological effects. Consequently,
these data are thus relevant when investigating the potential molec-
ular targets and the mechanisms of action of dietary ﬂavanols and
procyanidins in vivo.
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